6533b85afe1ef96bd12b9483
RESEARCH PRODUCT
Risk factors and molecular characterization of penile cancer
Anita ThomasJoren VanthoorComplex ConditionsGigi VosMaarten AlbersenIgor Tsaursubject
Oncologymedicine.medical_specialtybusiness.industrymedicine.drug_classUrology030232 urology & nephrologyIndividualized treatmentmedicine.diseaseSystemic therapyDacomitinibTyrosine-kinase inhibitorClinical trial03 medical and health scienceschemistry.chemical_compound0302 clinical medicinechemistry030220 oncology & carcinogenesisInternal medicineMonoclonalmedicineNimotuzumabPenile cancerbusinessmedicine.drugdescription
Purpose of review To provide a comprehensive summary of risk factors, molecular machinery as well as potential therapeutic targets with a particular focus on literature published in the last 2 years on prognosis and treatment of penile cancer (PeCa). Recent findings E2F, LAMC2, MAML2, ID1 and IGFBP2 proteins were demonstrated to play a critical role for aggressive tumor behavior and might predict poor survival in PeCa. PD-L1 axis was confirmed as a promising pathway to serve as a therapeutic target. A number of genetic alterations were illuminated. In clinical testing, pan-HER tyrosine kinase inhibitor dacomitinib provided promising results in chemo-naive and EGFR monoantibody nimotuzumab in chemotherapy-failed PeCa patients. Summary Knowledge of prognosis-relevant altered molecular pathways in PeCa is expanding paving the way for identification of potential therapeutic targets. Multicenter clinical trials in the setting of centralized PeCa care are warranted to foster effective marker-based individualized treatment strategies.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-03-01 | Current Opinion in Urology |